Trial Profile
A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary) ; Paricalcitol (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 11 Apr 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.
- 11 Apr 2023 Planned primary completion date changed from 31 Dec 2022 to 30 Jun 2023.
- 15 Feb 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.